te Dr Reddy's Q3 net profit falls 38% to Rs 303 crore | Zee Business

Dr Reddy's Q3 net profit falls 38% to Rs 303 crore

Dr Reddy's Q3 net profit falls 38% to Rs 303 crore
Shares of Dr Reddy's Labs were trading at Rs 2,490 apiece on BSE, down 2.80 per cent from previous close. Image source: PTI

Dr Reddy's Laboratories today posted a 38.51 per cent decline in consolidated net profit at Rs 302.7 crore for the third quarter ended December 31.

The company had posted a net profit of Rs 492.3 crore during the same period of previous fiscal.

Its total revenue from operations stood at Rs 3,834.1 crore for the quarter under review. It was Rs 3,723.2 crore during the third quarter of 2016-17, Dr Reddy's Labs said in a regulatory filing.

TRENDING NOW

The company said total revenue from operations for the quarter was not comparable consequent to introduction of Goods and Services Tax on July 1.

"Revenue from operations for the earlier periods (before July 1) included excise duty which is now subsumed in GST," it added.

Shares of Dr Reddy's Labs were trading at Rs 2,490 apiece on BSE, down 2.80 per cent from previous close.

Updated: Thu, Jan 25, 2018
02:12 pm
PTI
RELATED NEWS
Dr Reddy shares hit a series of record highs on all-round strong Q1 performance; what should investors do? Dr Reddy shares hit a series of record highs on all-round strong Q1 performance; what should investors do?
Dr Reddy’s out of Sensex pack; Tata Motors is new entrant - Check full list of 30 companies | Sensex Reshuffle December 2022 Dr Reddy’s out of Sensex pack; Tata Motors is new entrant - Check full list of 30 companies | Sensex Reshuffle December 2022
Dr Reddy's Laboratories share trade in green in early trade with over 1% surge after Q2 result: Check target given by brokerages Dr Reddy's Laboratories share trade in green in early trade with over 1% surge after Q2 result: Check target given by brokerages

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x